In the first quarter of this year, Samsung Biologics recorded its highest quarterly performance ever and set the mid-year performance bonus at the maximum level of 100% of the monthly basic salary.
According to the industry on the 8th, Samsung Biologics has confirmed the mid-year Target Achievement Incentive (TAI) accordingly. TAI is one of the company’s bonus systems that pays up to 100% of the monthly basic salary based on the performance evaluations of affiliated institutional sectors and business divisions, conducted once each in the first and second halves of the year.
Earlier, the company paid employees an Excess Profit Incentive (OPI) equivalent to 50% of their annual salary in January this year. OPI is a bonus system that pays up to 50% of the annual salary within a limit of 20% excess profit based on the previous year’s management performance. Samsung Group's bonus system is divided into TAI, paid biannually, and OPI, paid annually.
Samsung Biologics has paid both bonuses at the highest level since 2023. The company recorded a consolidated operating profit of 1.32 trillion won last year, an increase of 18.53% compared to the previous year. In the first quarter of this year, it also achieved a consolidated operating profit of 486.7 billion won, marking the largest quarterly performance in history. Samsung Biologics is the first among domestic pharmaceutical and biotechnology corporations to surpass 4 trillion won in annual sales.